Industry News

Biotechnology Industry News

An investigational drug for the…

September 22nd, 2026|FierceBiotech|

An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.

Vertex has reported positive phase…

September 22nd, 2026|FierceBiotech|

Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial.

Lexeo Therapeutics has agreed to…

September 22nd, 2026|FierceBiotech|

Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in three strategic collaborations to support its lead asset.

A phase 3 study of Otsuka and…

September 22nd, 2026|FierceBiotech|

A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis drug candidate has hit its primary endpoint, positioning the partners to talk to regulators about expedited approvals.

A phase 2 trial of Roche’s dual…

September 22nd, 2026|FierceBiotech|

A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with type 2 diabetes and overweight or obesity.

Boehringer Ingelheim and AI drug…

September 21st, 2026|FierceBiotech|

Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.

China is aiming to account for at…

September 21st, 2026|FierceBiotech|

China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status as a hotbed for innovative R&D.

Telix has struck a deal to buy ITM…

September 21st, 2026|FierceBiotech|

Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network.

Eli Lilly-backed TRex Bio and…

September 21st, 2026|FierceBiotech|

Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.

A midstage study of Cue…

September 21st, 2026|FierceBiotech|

A midstage study of Cue Biopharma’s hives drug candidate has hit its primary endpoint, emboldening the biotech to move the would-be challenger to Xolair into a phase 2b/3 trial.

Beacon Therapeutics has found the…

September 20th, 2026|FierceBiotech|

Beacon Therapeutics has found the light in a rare vision loss disease that has left larger companies in the dark. The biotech’s gene therapy for X-linked retinitis pigmentosa (XLRP) successfully improved visual acuity in a

Following Takeda’s historic…

September 18th, 2026|FierceBiotech|

Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of sleep disorders and into

The company has voluntarily…

September 18th, 2026|FierceBiotech|

The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.

Bristol Myers Squibb has axed the…

September 18th, 2026|FierceBiotech|

Bristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.

Electra Therapeutics is the latest…

September 18th, 2026|FierceBiotech|

Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing.

After former Legend Biotech CEO…

September 17th, 2026|FierceBiotech|

After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth.

A new biotech has sprung out of…

September 17th, 2026|FierceBiotech|

A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can quickly sober up people who have had too much to drink.